Saturday 17 October 2026
Export RXST’s income statement to Excel — free account
RxSight, Inc.
RXST Healthcare Medical Devices
RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS was flat and free cash flow fell 94.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
4.51
0.16
−3.43%
Follow RXST
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.59 | 3.17 | 2.00 | 1.57 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(310.26) | (381.42) | (23.36) | (20.97) | |
P/B ratio |
1.33 | 1.54 | 0.95 | 0.76 | |
Price to Tangible BV |
1.33 | 1.54 | 0.95 | 0.76 | |
EV/Sales |
1.13 | 1.61 | 0.44 | 0.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.60) | (14.00) | (3.20) | (0.47) | |
EV/FCF |
(7.22) | (11.23) | (2.60) | (0.40) | |
Quick Ratio |
11.29 | 9.58 | 8.78 | 3.57 | |
Current Ratio |
12.74 | 10.95 | 10.20 | 4.07 | |
Net Debt/EBITDA |
16.89 | 18.52 | 11.56 | 14.38 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.46 | 0.43 | 0.41 | 0.39 | |
Operating CF/Net income |
0.12 | 0.12 | 0.69 | 0.79 | |
Capex/Depreciation |
0.45 | 1.16 | 0.74 | 2.60 | |
Interest Coverage |
(3,044.50) | (2,834.00) | (5,943.00) | (4,590.00) | |
Research and Development Expense of Revenue |
29.86% | 27.31% | 30.66% | 27.38% | |
Selling, General and Administrative Expense of Revenue |
90.13% | 84.93% | 103.11% | 90.15% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
26.72% | 23.97% | 25.72% | 22.12% | |
Graham Net Nets |
0.68 | 0.59 | 0.95 | 1.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.79%) | (9.12%) | (18.34%) | (23.44%) | |
Free Cash Flow Yield |
(6.03%) | (4.54%) | (8.48%) | (13.58%) | |
Revenue per Share |
0.74 | 0.80 | 0.75 | 0.81 | |
Operating CF per Share |
(0.03) | (0.03) | (0.26) | (0.23) | |
Capex per Share |
(0.01) | (0.03) | (0.02) | (0.05) | |
Free Cash Flow per Share |
(0.04) | (0.06) | (0.28) | (0.28) | |
Cash per Share |
5.55 | 5.58 | 5.27 | 5.03 | |
Shareholders Equity per Share |
6.74 | 6.75 | 6.47 | 6.35 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.74 | 6.75 | 6.47 | 6.35 | |
Free Cash Flow |
(1.77) | (2.25) | (11.65) | (11.49) | |
Working Capital |
261.59 | 261.21 | 251.85 | 246.95 | |
Capital Expenditures |
(0.58) | (1.14) | (0.76) | (1.96) | |
Net Current Asset Value |
251.31 | 251.33 | 242.53 | 238.04 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.02 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
24.76 | 26.72 | 26.70 | 53.29 | |
Average Payables |
3.98 | 4.92 | 7.12 | 4.85 | |
Average Inventory |
25.31 | 26.78 | 29.22 | 31.09 | |
Average Assets |
309.50 | 315.19 | 308.52 | 330.85 | |
Average Common Equity |
276.62 | 278.46 | 273.31 | 270.68 |
Columns are period end dates